Clinical trials: Low Mood
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Sleep Initiation and Maintenance Disorders, Depression
STILDEP: Zolpidem in Depressive and Dysthimic Patients
Primary objective: To show that the combination of Zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute…
- Trial name
- NCT00292734
- Testing
- Zolpidem
- Where
- Hungary
- Volunteers
- 120 people
- Sponsor
- Sanofi
Major Depressive Disorder
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation…
- Trial name
- NCT00063206
- Testing
- DVS-233 SR
- Volunteers
- 247 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01255787
- Testing
- Vortioxetine
- Where
- 70 sites in Croatia, Finland and 14 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07553130
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 785 people, healthy volunteers welcome
- Sponsor
- Accexible
Respiratory Depression, Respiratory Failure
VitalThings Guardian Contactless Monitoring
This is a confirmatory study without any intervention. It is an uncontrolled, non-randomized and open-label study with measurements made with comparators, and it has a preset hypothesis for the primary endpoint.
- Conditions
- Respiratory Depression, Respiratory Failure, Deterioration, Clinical
- Trial name
- VINCENT (NCT06083272)
- Testing
- Vitalthings Guardian M10 fixed and M10 mobile
- Where
- Norway
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- VitalThings
Multiple Sclerosis, Relapsing-remitting
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina.
- Trial name
- NCT01080001
- Where
- Argentina
- Volunteers
- 71 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Depressive Disorder, Major
A Study to Evaluate the Benefit of Opti-Me Application to Different Treatments of MDD
Major depressive disorder (MDD) is a debilitating disease characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite.
- Trial name
- NCT04148612
- Testing
- Opti-Me
- Where
- 2 sites in Israel, Switzerland
- Volunteers
- 390 people
- Sponsor
- ElMindA Ltd
Depression in Patients With Bipolar Disorder
Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00622245
- Testing
- Lu AA34893, Quetiapine fumarate
- Where
- 50 sites in Australia, Austria and 16 more
- Volunteers
- 166 people
- Sponsor
- H. Lundbeck A/S
Depression
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
The main objective is to compare the pharmacokinetics in single dose, and effect of food on the trazodone hydrochloride pharmacokinetics prolonged-release tablets.
- Trial name
- NCT02785601
- Testing
- Trazodone Hydrochloride prolonged-release tablets
- Where
- Hong Kong
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Bipolar Disorder
A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00141271
- Testing
- Geodon (Ziprasidone)
- Where
- 72 sites in United States
- Volunteers
- 536 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Depression
Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets under fasted conditions
- Trial name
- NCT00754962
- Testing
- protriptyline
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Depressed Scar
Safety and Efficacy of Autologous Cultured Adipocytes in Patient With Depressed Scar
Autologous cultured adipocytes (ANTG-adip) is produced by well-established techniques including cell harvesting from lipoaspirates, expansion of adipose tissue derived stem cells, and differentiation into pure and immature…
- Trial name
- NCT00992147
- Testing
- Adipocell
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Anterogen Co., Ltd.
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard…
- Trial name
- NCT07620340
- Testing
- AI-Digital CBT, Cognitive Behavioural Therapy
- Volunteers
- 400 people
- Sponsor
- PsyScale
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company